Clinical Trial Update: A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer

View source ↗

Summary

A Phase III randomized trial comparing Mapisal to a urea hand-foot cream for preventing capecitabine-related hand-foot syndrome in patients with breast cancer o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastrointestinal Cancer

Drugs mentioned

• Mapisal
• Urea hand-foot cream

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine | Status: NO_LONGER_AVAILABLE